201 Haskins Way
South San Francisco, CA 94080
United States
650 695 0677
https://lyell.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 224
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Richard D. Klausner M.D. | Founder & Executive Chairman | 80k | N/A | 1952 |
Dr. Lynn Seely M.D., Ph.D. | President, CEO & Director | 430.69k | N/A | 1959 |
Mr. Stephen J. Hill | Chief Operating Officer | 1.04M | N/A | 1970 |
Dr. Gary Lee Ph.D. | Chief Scientific Officer | 639.91k | N/A | 1977 |
Ms. Elizabeth Homans | Consultant | 1.99M | N/A | 1966 |
Prof. Stanley R. Riddell M.D. | Founder & Scientific Advisor | N/A | N/A | N/A |
Dr. Crystal L. Mackall M.D. | Founder & Scientific Advisor | N/A | N/A | 1961 |
Nellie Dillery | Director of Accounting | N/A | N/A | N/A |
Ms. Ellen Rose | Senior Vice President of Communications & Investor Relations | N/A | N/A | N/A |
Mr. Matthew Lang J.D. | Chief Business Officer, Chief Legal Officer & Corporate Secretary | N/A | N/A | 1976 |
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 8; Compensation: 9.